drugset / Trial / NCT01887600

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

NCT01887600

Phase 3 Completed 594 enrolled Astellas Pharma Europe B.V. Kyntra Bio · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood. The purpose of the study was to see if Roxadustat is both effective and safe as a treatment for anemia in patients with chronic kidney disease.

Timeline

Start
2013-09-03
Primary completion
2017-11-01
Completion
2017-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Roxadustat Small molecule

Indications

No indication recorded.